Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ADMP

Adamis Pharmaceuticals (ADMP) Stock Price, News & Analysis

Adamis Pharmaceuticals logo

About Adamis Pharmaceuticals Stock (NASDAQ:ADMP)

Key Stats

Today's Range
N/A
50-Day Range
$0.77
$3.99
52-Week Range
N/A
Volume
119,800 shs
Average Volume
811,695 shs
Market Capitalization
$7.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ADMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ADMP Stock News Headlines

DMK Pharmaceuticals Corp DMK
Forget NVDA. Put $1,000 into this stock now
A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW kind of AI stock.tc pixel
See More Headlines

ADMP Stock Analysis - Frequently Asked Questions

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) announced its earnings results on Thursday, March, 31st. The specialty pharmaceutical company reported ($4.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.80) by $1.40. Adamis Pharmaceuticals had a negative trailing twelve-month return on equity of 420.53% and a negative net margin of 502.73%.

Adamis Pharmaceuticals's stock reverse split on Monday, May 22nd 2023.The 1-70 reverse split was announced on Monday, May 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adamis Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and FuelCell Energy (FCEL).

Company Calendar

Last Earnings
3/31/2022
Today
9/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADMP
CIK
887247
Fax
N/A
Employees
11
Year Founded
2006

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.48 million
Net Margins
-502.73%
Pretax Margin
-471.80%
Return on Equity
-420.53%
Return on Assets
-256.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.23
Quick Ratio
0.19

Sales & Book Value

Annual Sales
$4.76 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.26) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
9,360,000
Free Float
9,237,000
Market Cap
$7.26 million
Optionable
Optionable
Beta
1.27

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:ADMP) was last updated on 9/18/2025 by MarketBeat.com Staff
From Our Partners